Research Topics
| Ann M LeenSummaryAffiliation: Baylor College of Medicine Country: USA Publications
| Collaborators
|
Detail Information
Publications
Fiber-modified adenoviruses generate subgroup cross-reactive, adenovirus-specific cytotoxic T lymphocytes for therapeutic applicationsAnn M Leen
Center for Cell and Gene Therapy, Department of Pediatrics, 6621 Fannin S, MC 3-3320, Houston, TX 77030, USA
Blood 103:1011-9. 2004..This is the first report of a simple and reproducible method to activate and expand Ad-specific cytotoxic T lymphocytes (CTLs), which should be protective against the range of different Ad subtypes that affect transplant recipients...- Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphomaKarin C Straathof
Center for Cell and Gene Therapy, Baylor College of Medicine, Methodist Hospital and Texas Children's Hospital, Houston, TX 77030, USA
J Immunol 175:4137-47. 2005..These new LMP2 epitopes broaden the diversity of HLA alleles with available epitopes, and, in particular, those epitopes conserved between EBV strains provide valuable tools for immunotherapy and immune monitoring... 
Challenges of T cell therapies for virus-associated diseases after hematopoietic stem cell transplantationAnn M Leen
The Methodist Hospital, Texas Children s Hospital, Center for Cell and Gene Therapy, Baylor College of Medicine, 1102 Bates Street, Houston, TX 77030, USA
Expert Opin Biol Ther 10:337-51. 2010..However, alternative donor HSCT are associated with three major complications i) graft rejection; ii) graft-versus-host disease (GvHD); and iii) delayed immune reconstitution leading to viral infections and relapse...- Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantationAnn M Leen
Center for Cell and Gene Therapy and Departments of Pediatrics, Immunology, Medicine, and Virology, Baylor College of Medicine, Texas Children s Hospital and The Methodist Hospital, Houston, TX 77030, USA
Blood 114:4283-92. 2009..This trial was registered at www.clinicaltrials.gov as #NCT00590083... - Cytotoxic T lymphocytes as immune-therapy in haematological practiceAnn M Leen
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, and Texas Children s Hospital, Houston, TX 77030, USA
Br J Haematol 143:169-79. 2008.... - Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapyAnn M Leen
Center for Cell and Gene Therapy, Baylor College of Medicine, 6621 Fannin Street, MC 3 3320, Houston, TX 77030, USA
J Virol 82:546-54. 2008.... - Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphomaUlrike Gerdemann
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Texas Children s Hospital, Houston, Texas 77030, USA
Mol Ther 19:2258-68. 2011..Infusion of such multispecific monocultures may extend the benefits of CTL therapy to treatment even of EBV negative HL and NHL... 
Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein-Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplantUluhan Sili
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, The Methodist Hospital, Houston, Texas 77030, USA
Cytotherapy 14:7-11. 2012..We now provide the details and logistics of T cell manufacture...- Genetic modification of T cells with IL-21 enhances antigen presentation and generation of central memory tumor-specific cytotoxic T-lymphocytesAnjum S Kaka
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX, USA
J Immunother 32:726-36. 2009.... - Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapyYuriko Fujita
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Texas Children s Hospital, Houston, TX 77030, USA
J Immunother 31:665-74. 2008..By simultaneously expanding a portion of the selected product, we can characterize phenotype and function of the infused product and link them with subsequent in vivo outcome... - Using dendritic cell maturation and IL-12 producing capacity as markers of function: a cautionary taleAnjum S Kaka
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
J Immunother 31:359-69. 2008.... - Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopesPatrick J Hanley
Department of Immunology, Baylor College of Medicine, Texas Children s Hospital and The Methodist Hospital, Center for Cell and Gene Therapy, Houston, TX 77030, USA
Blood 114:1958-67. 2009..This study is registered at www.clinicaltrials.gov as NCT00078533... - Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantationKenneth P Micklethwaite
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, Houston, TX, USA
Blood 115:2695-703. 2010..This approach may prove beneficial for patients with high-risk B-ALL who have recently received an HSC or CB transplant and are at risk of infection and relapse... - Antigen-specific cytotoxic T lymphocytes can target chemoresistant side-population tumor cells in Hodgkin lymphomaJessica A Shafer
Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, The Methodist Hospital and Texas Children s Cancer Center, Houston, TX 77030, USA
Leuk Lymphoma 51:870-80. 2010..This study suggests that chemoresistant HL SP cells can be targeted by the immune system, providing a rationale for combined chemotherapy and immunotherapy for the treatment of HL... - Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transferCatherine M Bollard
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
Blood 110:2838-45. 2007..This study is registered at http://www.cancer.gov/clinicaltrials (protocol IDs: BCM-H-9936, NCT00062868, NCT00070226)... - Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex)Juan F Vera
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
J Immunother 33:305-15. 2010..This bioprocess optimization increased T-cell output while decreasing the complexity and cost of CTL manufacture, making cell therapy more accessible... - Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individualsAnn M Leen
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, Texas 77030, USA
Nat Med 12:1160-6. 2006..Monoculture-derived multispecific CTL infusion could provide a safe and efficient means to restore virus-specific immunity in the immunocompromised host... - Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantationUlrike Gerdemann
Center for Cell and Gene Therapy, Baylor College of Medicine, Methodist Hospital, Texas Children s Hospital, Houston, TX 77030, USA
Blood 121:207-18. 2013..Thus, we conclude that adoptive T-cell immunotherapy for HHV6 is a practical objective and that the peptide and epitope tools we describe will allow such cells to be prepared, administered, and monitored in human subjects... - Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cellsAnn M Leen
Center for Cell and Gene Therapy, Department of Pediatrics, 6621 Fannin St, MC 3-3320, Houston, TX, USA
Blood 104:2432-40. 2004..Thus, by exploiting these peptide targets, it is possible to prepare a T-cell population capable of reacting with most adenoviruses that cause disease in immunocompromised patients... - Nucleofection of DCs to generate Multivirus-specific T cells for prevention or treatment of viral infections in the immunocompromised hostUlrike Gerdemann
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Texas Children s Hospital, Houston, Texas 77030, USA
Mol Ther 17:1616-25. 2009..These CTL generation procedures should increase the feasibility and applicability of T-cell therapy... - Rapidly generated multivirus-specific cytotoxic T lymphocytes for the prophylaxis and treatment of viral infectionsUlrike Gerdemann
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Texas Children s Hospital, Houston, TX, USA
Mol Ther 20:1622-32. 2012..Our approach can be readily introduced into clinical practice and should be a cost-effective alternative to common antiviral prophylactic agents for allogeneic hematopoietic stem cell transplant (HSCT) recipients... - Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4Conrad R Cruz
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas
Clin Cancer Res 17:7058-66. 2011..Furthermore, epigenetic modification by clinically available demethylating agents can enhance MAGE-A4 expression in previously MAGE-negative tumors... - Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12Aaron E Foster
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, 6621 Fannin Street, Houston, TX 77030, USA
J Immunother 30:506-16. 2007..Thus, T cells provide a platform for the generation of autologous APC that can be customized to express both antigens and therapeutic molecules for the induction of antigen-specific T cell immunity... - Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7Juan F Vera
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Houston, Texas 77030, USA
Mol Ther 17:880-8. 2009..This approach may allow selective expansion of CTLs without the unwanted effects associated with IL-2... - Adenoviral infections in hematopoietic stem cell transplantationAnn M Leen
Center for Cell and Gene Therapy, Baylor College of Medicine, and The Methodist Hospital, Houston, Texas 77030, USA
Biol Blood Marrow Transplant 12:243-51. 2006..We discuss the advantages and limitations of T-cell therapy for the prophylaxis and treatment of adenovirus infection posttransplantation... - PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptorYozo Nakazawa
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
Mol Ther 19:2133-43. 2011..Our results demonstrate that PB can be used to redirect virus-specific CTLs to tumor targets, which should prolong tumor-specific T cell survival in vivo producing more efficacious immunotherapy... - High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cellsConcetta Quintarelli
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
Blood 117:3353-62. 2011..These PRAME-directed CTLs did not affect normal hematopoietic progenitors, indicating that this approach may be of value for immunotherapy of PRAME(+) hematologic malignancies... - Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignanciesCarlos A Ramos
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX77030, USA
J Immunother 36:66-76. 2013..Because our technique is scalable and good-manufacturing procedures-compliant, these lines could be used for adoptive cellular immunotherapy of patients with HPV16 cancers... - Generation of polyclonal CMV-specific T cells for the adoptive immunotherapy of glioblastomaAlexia Ghazi
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
J Immunother 35:159-68. 2012..Infusion of such CMV-specific T-cell lines may extend the benefits of T-cell therapy to patients with CMV GBMs... - Engineered T cells for pancreatic cancer treatmentUsha L Katari
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, Houston, TX 77030, USA
HPB (Oxford) 13:643-50. 2011..The aim of this study is to develop an adoptive T cell transfer approach to target tumours expressing prostate stem cell antigen (PSCA), a tumour-associated antigen that is frequently expressed by pancreatic cancer cells... - Adenovirus as an emerging pathogen in immunocompromised patientsAnn M Leen
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, and Texas Children s Hospital, Houston, TX 77030, USA
Br J Haematol 128:135-44. 2005.... - Improving T cell therapy for cancerAnn M Leen
Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, Texas 77030, USA
Annu Rev Immunol 25:243-65. 2007..In this review, we discuss current, promising strategies to improve adoptive T cell therapy for the treatment of cancer... - Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experienceConrad Russell Cruz
Dan L Duncan Cancer Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Texas Children s Hospital, Houston, Texas 77030, USA
Cytotherapy 12:743-9. 2010..Recent catastrophic reactions to 'first-in-man' biologic agents have emphasized the importance of this rule for initial studies of new products. The value of such monitoring for better established agents is less obvious...